Tuzun E, Meriggioli MN, Rowin J, Yang H, Christadoss P.
Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-gamma. There was a direct correlation between plasma IL-6, TNF-alpha and IFN-gamma levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-gamma levels attained better clinical improvement following etanercept treatment.
重症肌无力血清IL-6和IFN-gamma低者可通过依那西普治疗获益
一项前瞻性开放性研究表明，激素依赖性重症肌无力病人应用依那西普（TNF-α拮抗剂, etanercept ）后症状可改善。但血清乙酰胆碱受体抗体水平却无明显变化，依那西普可提高血浆补体C3水平、循环免疫复合物、IL-10和IFN-gamma。血浆IL-6、TNF-alpha和IFN-gamma水平与治疗后的临床评分有直接相关。此外，治疗前IL-6和IFN-gamma水平低者获得的治疗效果更佳。
J Autoimmun. 2005 May;24(3):261-8.
